Eli Lilly and Company

Tweet this page
<
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 17 Mar 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

800,000€ - 899,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

1.9 Fte (7)

Lobbyists with EP accreditation

6

High-level Commission meetings

18

Lobbying Costs over the years

  • Info

    Eli Lilly and Company   (Lilly)

    EU Transparency Register

    04657143399-39 First registered on 02 Apr 2010

    Goals / Remit

    Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

    Headquartered in the US, Lilly has more than 42,978 employees worldwide. In 2023 global revenue was approx. $34.12 billion, of which 27.3% were invested in R&D. Average cost to discover and develop a new drug: $2.6 billion. Average length of time from discovery to patient: 10 years.

    ( https://investor.lilly.com/financials.cfm )

    Main EU files targeted

    EU Pharmaceutical Strategy, EU pharmaceutical legislation, Intellectual Property Rights and incentives - including Orphan Medicinal Products, Paediatric medicines and Anti-Microbial Resistance (AMR), Free Trade Agreements - EU/US, EU/UK, EU Beating Cancer Plan, EU HTA Regulation, EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes, European Chemicals Agency (ECA), Packaging and Packaging Waste Regulation, REACH, Urban Waste Water Treatment Directive, per-and polyfluoroalkyl substances (PFAS), Industrial strategy (including bio-manufacturing), Competition law, Horizon Europe, Innovative Healthcare Initiative (IHI), European Medicines Agency (EMA), Clinical Trials Regulation, Medical Devices Regulation, Falsified Medicines Directive, Cross-border Healthcare Directive, Data Protection Regulation, Public Procurement Directive, Substances of Human Origin (SoHO), Transparency Directive, Artificial intelligence, Digital / Digital health, European Health Data Space. Other policy areas of interest include Innovation, Research and Development, Public-Private Partnerships, Mergers and acquisitions, Life sciences, Biopharmaceuticals, Manufacturing including Active Pharmaceutical Ingredients (API), Health outcomes, Real world evidence, Pricing, reimbursement and market access to medicines, Alzheimer's research, cancer, diabetes, immunology, obesity, pain, healthcare sustainability, global health pandemics, clinical trials transparency, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.

    Address

    Head Office
    Lilly Corporate Center Indianapolis Indiana
    Indianapolis 46285
    UNITED STATES
    EU Office
    Rue du Marquis 1/4B Markiesstraat
    Brusselles / Brussel B-1000
    BELGIUM

    Website

  • People

    Total lobbyists declared

    7

    Employment timeLobbyists
    50%3
    10%4

    Lobbyists (Full time equivalent)

    1.9

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    6 accreditations were / are live (in bold) for the selected state of 25 May 2024

    Name Start date End Date
    Maurizio GUIDI 15 Dec 2023 13 Dec 2024
    Ludovica FLORENZANO 04 Apr 2024 02 Oct 2024
    Antonella ETTORRE 15 Dec 2023 13 Dec 2024
    Fanny VERSPEELT 16 Feb 2024 14 Feb 2025
    Aoife GALLAGHER 15 Dec 2023 13 Dec 2024
    Doris SCHERNHAMMER 15 Dec 2023 13 Dec 2024
    Mr Pierluca ARIETTI 16 Dec 2023 21 Mar 2024
    Aoife GALLAGHER 25 Jan 2023 15 Dec 2023
    Doris SCHERNHAMMER 25 Jan 2023 15 Dec 2023
    Antonella ETTORRE 24 Jan 2023 15 Dec 2023
    Mr Goncalo FERREIRA-PINTO-MENDES 24 Nov 2022 06 May 2023
    Mr Pierluca ARIETTI 19 Nov 2022 18 Nov 2023
    Maurizio GUIDI 19 Nov 2022 18 Nov 2023
    Ms Sonia Ujupan 24 Sep 2022 23 Sep 2023
    Mr Goncalo PINTO MENDES 20 Oct 2021 20 Oct 2022
    Doris SCHERNHAMMER 13 May 2021 13 May 2022
    Aoife GALLAGHER 11 May 2021 11 May 2022
    Ms Sonia Ujupan 05 Mar 2021 05 Mar 2022
    Mr Gerd KRAH 27 Feb 2020 27 Feb 2021
    Ms Sonia Ujupan 05 Feb 2020 05 Feb 2021
    Aoife GALLAGHER 03 Oct 2019 03 Oct 2020
    Ms Arantzazu MUGICA GOICOECHEA 30 Mar 2019 01 Apr 2020
    Ms Sonia Ujupan 28 Nov 2018 19 Nov 2019
    Doris SCHERNHAMMER 10 Nov 2018 09 Nov 2019
    Mr Davide RUFFO 09 Nov 2018 09 Nov 2019
    Aoife GALLAGHER 24 May 2018 24 May 2019
    Ms Sonia Ujupan 13 Nov 2017 20 Oct 2018
    Doris SCHERNHAMMER 01 Nov 2017 31 Oct 2018
    Doris SCHERNHAMMER 22 Nov 2016 01 Nov 2017
    Aoife GALLAGHER 22 Nov 2016 19 Nov 2017
    Ms Sonia Ujupan 16 Nov 2016 13 Nov 2017
    Ms Elisa Irlandese 15 Sep 2016 14 Sep 2017
    Mr Olivier ESPEISSE 14 Jan 2016 13 Jan 2017
    Doris SCHERNHAMMER 13 Jan 2016 22 Nov 2016
    Ms Athanasia Kanli 17 Nov 2015 12 Nov 2016
    Aoife GALLAGHER 23 Jul 2015 20 Jul 2016
    Doris SCHERNHAMMER 27 Jan 2015 13 Jan 2016
    Ms Athanasia Kanli 10 Dec 2014 17 Nov 2015
    Mr Alexander Josef ANTON 04 Apr 2013 19 Nov 2013
    Mr Hugh Thomas PULLEN 26 Mar 2013 23 Mar 2014
    Mr Alexander Josef ANTON 24 Feb 2012 01 Mar 2013
    Mr Hugh Thomas PULLEN 24 Feb 2012 01 Mar 2013

    Complementary Information

    Note: 3 colleagues are full-time engaged in the Brussels office and will spend approximately 30% - 50% of their time on relevant EU affairs, with another in the Brussels office and 4 outside the Brussels office. A few other colleagues whereas spend a fraction of their time (<5%).

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Eli Lilly and Company is a member of the following associations and bodies: European Federation of Pharmaceutical Industries and Associations (EFPIA), The European Association of Bioindustries (EuropaBio), American Chamber of Commerce to the European Union (AmChamEU), American European Community Association, Kangaroo Group, European Business Summit, Belgian Brain Council, ABC Global Alliance, Transforming Breast Cancer Together, Pharmaceutical Research and Manufacturers of America (PhRMA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    800,000€ - 899,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    concilius 50,000€ - 99,999€
    covington & burling llp 50,000€ - 99,999€
    vulcan consulting limited 50,000€ - 99,999€
    acumen public affairs 50,000€ - 99,999€
    fti consulting 10,000€ - 24,999€
    rud pedersen public affairs brussels 0€ - 10,000€
    fleishman-hillard 25,000€ - 49,999€

    Intermediaries for current year

    Name
    fleishman-hillard
    fti consulting
    acumen public affairs
    covington & burling llp
    concilius

    Closed year Costs

    800,000€ - 899,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    Represented through several trade bodies and industry associations, for example EFPIA, EuropaBio, AmChamEU. Participating in events on trade, industrial, health and life science policy, for example European Health Summit, Kangaroo Group and The Parliament magazine debates. Meeting with policy makers in the EU institutions. Engaging with other public policy stakeholders.

    Other activities

    None declared

  • Meetings

    Meetings

    18 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard